Methylone-induced hyperthermia and lethal toxicity: Role of the dopamine and serotonin transporters

Behavioural Pharmacology

Volumn 26, Issue 4, 2015, Pages 345-352

  Piao, Ying Shan ^a,h   Hall, Frank Scott ^d   Moriya, Yuki ^a   Ito, Miki ^a   Ohara, Arihisa ^a   Kikura Hanajiri, Ruri ^b   Goda, Yukihiro ^b   Lesch, Klaus Peter ^g   Murphy, Dennis L ^e   Uhl, George R ^f   Sora, Ichiro ^a,c  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d MEDICAL COLLEGE OF OHIO   (United States)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^f NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

dopamine; hyperthermia; knockout mice; lethality; methylone; serotonin; toxicity; transporter

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMPHETAMINE; DOPAMINE TRANSPORTER; METHYLONE; RACLOPRIDE; SEROTONIN TRANSPORTER; BENZAZEPINE DERIVATIVE; CENTRAL STIMULANT AGENT; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; METHAMPHETAMINE; SLC6A4 PROTEIN, MOUSE;

ARTICLE; BODY TEMPERATURE MEASUREMENT; COMPARATIVE TOXICOLOGY; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; ELECTRONIC THERMOMETER; FEMALE; HYPERTHERMIA; HYPOTHERMIA; LD50; LETHALITY; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN FUNCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL MODEL; ANTAGONISTS AND INHIBITORS; BODY TEMPERATURE; CHEMICALLY INDUCED; DRUG EFFECTS; FEVER; GENETICS; KNOCKOUT MOUSE; METABOLISM; MORTALITY; PHYSIOLOGY;

ANIMALS; BENZAZEPINES; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FEVER; MALE; METHAMPHETAMINE; MICE, KNOCKOUT; MODELS, ANIMAL; RACLOPRIDE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84937723970     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000135     Document Type: Article

References (52)

1. Baumann MH (2014). Awash in a sea of' 'bath salts': implications for biomedical research and public health. Addiction 109:1577-1579.
2. Baumann MH, Clark RD, Franken FH, Rutter JJ, Rothman RB (2008). Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single highdose binges. Neuroscience 152:773-784.
3. Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. (2012). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37:1192-1203.
4. Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A, et al. (1998). Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporterdeficient mice. Mol Pharmacol 53:649-655.
5. Bossong MG, Van Dijk JP, Niesink RJ (2005). Methylone and mCPP, two new drugs of abuse? Addict Biol 10:321-323.
6. Boulanger-Gobeil C, St-Onge M, Laliberte M, Auger PL (2012). Seizures and hyponatremia related to ethcathinone and methylone poisoning. J Med Toxicol 8:59-61.
7. Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W Jr, et al. (1994). Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 268:1571-1580.
8. Bronstein DM, Hong JS (1995). Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality. J Pharmacol Exp Ther 274:943-950.
9. Brown PL, Kiyatkin EA (2004). Brain hyperthermia induced by MDMA (ecstasy): modulation by environmental conditions. Eur J Neurosci 20:51-58.
10. Brown PL, Wise RA, Kiyatkin EA (2003). Brain hyperthermia is induced by methamphetamine and exacerbated by social interaction. J Neurosci 23:3924-3929.
11. Brunt TM, Poortman A, Niesink RJ, van den Brink W (2011). Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 25:1543-1547.
12. Carvalho M, Carvalho F, Remiao F, de Lourdes Pereira M, Pires-das-Neves R, de Lourdes Bastos M (2002). Effect of 3,4-methylenedioxymethamphetamine ("ecstasy") on body temperature and liver antioxidant status in mice: influence of ambient temperature. Arch Toxicol 76:166-172.
13. Cozzi NV, Sievert MK, Shulgin AT, Jacob P 3rd, Ruoho AE (1999). Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 381:63-69.
14. Dafters RI (1995). Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol Behav 58:877-882.
15. Dal Cason TA, Young R, Glennon RA (1997). Cathinone: an investigation of several N-Alkyl and methylenedioxy-substituted analogs. Pharmacol Biochem Behav 58:1109-1116.
16. Dams R, De Letter EA, Mortier KA, Cordonnier JA, Lambert WE, Piette MH, et al. (2003). Fatality due to combined use of the designer drugs MDMA and PMA: a distribution study. J Anal Toxicol 27:318-322.
17. Davidson C, Gow AJ, Lee TH, Ellinwood EH (2001). Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36:1-22.
18. Den Hollander B, Rozov S, Linden AM, Uusi-Oukari M, Ojanpera I, Korpi ER (2013). Long-term cognitive and neurochemical effects of "bath salt" designer drugs methylone and mephedrone. Pharmacol Biochem Behav 103:501-509.
19. Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A (2013). Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85:1803-1815.
20. Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC, et al. (2003). Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) 166:202-211.
21. Fauchey V, Jaber M, Caron MG, Bloch B, Le Moine C (2000). Differential regulation of the dopamine D1, D2 and D3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter. Eur J Neurosci 12:19-26.
22. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007). New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47:681-698.
23. Gatch MB, Taylor CM, Forster MJ (2013). Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones. Behav Pharmacol 24:437-447.
24. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996). Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612.
25. Greene SL, Dargan PI, O'Connor N, Jones AL, Kerins M (2003). Multiple toxicity from 3,4-methylenedioxymethamphetamine ("ecstasy"). Am J Emerg Med 21:121-124.
26. Henry JA, Jeffreys KJ, Dawling S (1992). Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340:384-387.
27. Ito M, Numachi Y, Ohara A, Sora I (2008). Hyperthermic and lethal effects of methamphetamine: roles of dopamine D1 and D2 receptors. Neurosci Lett 438:327-329.
28. Karlsson L, Andersson M, Kronstrand R, Kugelberg FC (2014). Mephedrone, methylone and 3,4-methylenedioxypyrovalerone (MDPV) induce conditioned place preference in mice. Basic Clin Pharmacol Toxicol 115:411-416.
29. Lahti RA, Evans DL, Stratman NC, Figur LM (1993). Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol 236:483-486.
30. Lopez-Arnau R, Martinez-Clemente J, Pubill D, Escubedo E, Camarasa J (2012). Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br J Pharmacol 167:407-420.
31. Lopez-Arnau R, Martinez-Clemente J, Abad S, Pubill D, Camarasa J, Escubedo E (2014). Repeated doses of methylone, a new drug of abuse, induce changes in serotonin and dopamine systems in the mouse. Psychopharmacology (Berl) 231:3119-3129.
32. Malberg JE, Seiden LS (1998). Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18:5086-5094.
33. Mallick A, Bodenham AR (1997). MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. J Accid Emerg Med 14:336-338.
34. Marusich JA, Grant KR, Blough BE, Wiley JL (2012). Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice. Neurotoxicology 33:1305-1313.
35. Mechan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, Green AR (2002). The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br J Pharmacol 135:170-180.
36. Melega WP, Lacan G, Harvey DC, Huang SC, Phelps ME (1998). Dizocilpine and reduced body temperature do not prevent methamphetamine-induced neurotoxicity in the vervet monkey: [11C]WIN 35,428-positron emission tomography studies. Neurosci Lett 258:17-20.
37. Miller DB, O'Callaghan JP (1994). Environment-, drug-And stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:752-760.
38. Nagai F, Nonaka R, Satoh Hisashi Kamimura K (2007). The effects of nonmedically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559:132-137.
39. Namiki M, Mori T, Sawaguchi T, Ito S, Suzuki T (2005). Underlying mechanism of combined effect of methamphetamine and morphine on lethality in mice and therapeutic potential of cooling. J Pharmacol Sci 99:168-176.
40. Numachi Y, Ohara A, Yamashita M, Fukushima S, Kobayashi H, Hata H, et al. (2007). Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Eur J Pharmacol 572:120-128.
41. Pearson JM, Hargraves TL, Hair LS, Massucci CJ, Frazee CC 3rd, Garg U, et al. (2012). Three fatal intoxications due to methylone. J Anal Toxicol 36:444-451.
42. Shimizu E, Watanabe H, Kojima T, Hagiwara H, Fujisaki M, Miyatake R, et al. (2007). Combined intoxication with methylone and 5-MeO-MIPT. Prog Neuropsychopharmacol Biol Psychiatry 31:288-291.
43. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, et al. (2013). Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458-470.
44. Sogawa C, Sogawa N, Ohyama K, Kikura-Hanajiri R, Goda Y, Sora I, et al. (2011). Methylone and monoamine transporters: correlation with toxicity. Curr Neuropharmacol 9:58-62.
45. Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R, et al. (1998). Cocaine reward models: conditioned place preference can be established in dopamine-And in serotonin-transporter knockout mice. Proc Natl Acad Sci USA 95:7699-7704.
46. Sora I, Hall FS, Andrews AM, Itokawa M, Li XF, Wei HB, et al. (2001). Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci USA 98:5300-5305.
47. Sora I, Li B, Igari M, Hall FS, Ikeda K (2010). Transgenic mice in the study of drug addiction and the effects of psychostimulant drugs. Ann NY Acad Sci 1187:218-246.
48. Steinkellner T, Freissmuth M, Sitte HH, Montgomery T (2011). The ugly side of amphetamines: short-And long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-Amphetamine. Biol Chem 392:103-115.
49. Stokes AH, Hastings TG, Vrana KE (1999). Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 55:659-665.
50. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G, et al. (1991). Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350:614-619.
51. Warrick BJ, Wilson J, Hedge M, Freeman S, Leonard K, Aaron C (2012). Lethal serotonin syndrome after methylone and butylone ingestion. J Med Toxicol 8:65-68.
52. Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F (2011). Mephedrone, new kid for the chop? Addiction 106:154-161.